logo-loader
RNS
SkinBioTherapeutics PLC

SkinBioTherapeutics - Director/PDMR Shareholding

RNS Number : 2532W
SkinBioTherapeutics PLC
16 April 2019
 

SkinBioTherapeutics plc

 

Director Dealing

 

Manchester, UK - 16 April 2019 - SkinBioTherapeutics plc (AIM: SBTX - "SkinBioTherapeutics" or the "Company"), a life science company focused on skin health, announces it was notified on 15 April 2019, that Dr Cathy Prescott, a Non-Executive Director of the Company, acquired 56,112 ordinary shares on 15 April 2019 at a price of 17.82p per share.

 

Dr Prescott now holds 56,112 ordinary shares in the Company, representing 0.04% of the Company's issued share capital.

 

The information communicated within this announcement is deemed to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 and has been arranged for release by Doug Quinn, CFO of the Company. Upon the publication of this announcement, this inside information is now considered to be in the public domain.

 

For more information please contact:

SkinBioTherapeutics plc

Dr Cath O'Neill, CEO

Doug Quinn, CFO

 

Tel: +44 (0) 161 468 2760

Cairn Financial Advisers LLP (Nominated Adviser)

Tony Rawlinson / Sandy Jamieson / Richard Nash

 

Tel: +44 (0) 20 7213 0880

Turner Pope Investments (Joint Broker)

Ben Turner / James Pope

 

SP Angel Corporate Finance (Joint Broker)

Vadim Alexandre / Abigail Wayne

 

Tel: +44 (0) 20 3621 4120

 

 

Tel: +44 (0) 20 3470 0470

Instinctif Partners

Melanie Toyne-Sewell / Deborah Bell

Tel: +44 (0) 20 7457 2020

SkinBio@instinctif.com

 

 

About SkinBioTherapeutics plc

SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Dr. Catherine O'Neill and Professor Andrew McBain.

SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to the skin. The Company has shown that the SkinBiotix® platform can improve the barrier effect of skin models, protect skin models from infection and repair skin models. Proof of principle studies have shown that the SkinBiotix® platform has beneficial attributes applicable to each of these areas. 

SkinBioTherapeutics received seed funding from the Tech Transfer office of the University of Manchester for the discovery of SkinBiotix®. The platform was subsequently spun out of the University of Manchester in March 2016 and was funded by OptiBiotix (AIM: OPTI).

The Company joined AIM in April 2017, concurrent with raising £4.5 million from a placing of new ordinary shares.

The Company is based in Manchester, UK. For more information, visit www.skinbiotherapeutics.com.

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

Dr Cathy Prescott

2

Reason for notification

 Acquisition of shares

a.

Position/Status

Non-Executive Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

SkinBioTherapeutics Plc

b.

LEI

213800YMQOCB23FX6I06

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary shares of 1p each

 

 

ISIN: GB00BF33H870

 

b.

Nature of the transaction

 Share purchase

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s) per share

Volume(s)

 

17.82p

56,112

 

 

 

d.

Aggregated information

 

- Aggregated Volume

 

- Price

 

 

56,112

 

17.82p

 

e.

Date of the transaction

15th April 2019

f.

Place of the transaction

London Stock Exchange

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHEELFFKZFXBBV
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read